presenting with unexplained multiple systemic features associated with objective abnormalities on investigations like raised inflammatory markers; their strategies to rule out rare conditions and to be able to come to the diagnosis especially in these challenging scenarios. Key learning points: Main learning points for me and my colleagues are seeking prompt and close collaboration with all the other relevant specialties when assessing a patient presenting with unexplained systemic illness; where there is diagnostic uncertainty. Besides, as per this case, the combination of inflammatory eye conditions and systemic symptoms should prompt a general work up to exclude autoimmune conditions such as sarcoidosis. A delayed diagnosis such as cardiac sarcoidosis may have life-threatening consequences and the ophthalmologist may be the first specialty to pick up these rare conditions as was in this case. Introduction: We report the outcome of an atypical haemolytic uraemic syndrome (aHUS) in a 30 year old British-Asian prima-gravida with Lupus/Sjogren's Syndrome overlap. A combination of therapies including plasma exchange, methylprednisolone pulses and compassionate use of Eculizumab, a c5 inhibiting monoclonal antibody, was lifesaving. The appearance of a microangiopathic haemolytic anaemia (MAHA) and thrombocytopaenia in pregnancy is challenging. The causes can include sepsis, placental abnormalities, anti-phospholipid syndrome, and thrombotic microangiopathies (TMA) including pre-eclampsia/HELLP (haemolysis, elevated liver enzymes, low platelets) syndromes, thrombotic thrombocytopaenic purpura (TTP) and a spectrum of complement mediated conditions thrombotic microangiopathies (also known as atypical haemolytic uraemic syndrome, aHUS). The timings of these complications can vary, presenting anywhere from first trimester to the postpartum period. In a pregnant woman who also has lupus, these presentationscanmimicalupusflare,they areassociated withsignificantmaternal and foetal mortality; even with survival there can be life-changing sequelae. Eculizumab is a recombinant humanized monoclonal antibody which acts as aterminal inhibitorof the complementcascadeand was approved for use in aHUS in the UK in 2015: use in lupus is rare and illustrates important learning points. Case description: A 30 year old British-Asian woman had a diagnosis of with lupus/Sjogren's syndrome overlap and non-progressive interstitial lung disease. Her autoantibody profile included positivity for anti-Ro and anti-Laantibodiesandforrheumatoidfactor. ComplementC3andC4lev-els and quantitative double stranded DNA remained in physiological range and she had persistent low level haematuria and proteinuria with preserved renal function. She was maintained on 200 mg of hydroxychloroquine and up to 20 mg of prednisolone daily, having failed a trial of methotrexate. Other disease modifying anti-rheumatic drugs such as azathioprine were considered but this choice was complicated by low thiopurine methyltransferase level, and the patient declined. She had one episode of post-anti-streptolysin O positive arthralgia and renal impairment which settled with an increased steroid course. Three years after initial diagnosis she was able to conceive naturally. In early pregnancy, her condition was reported as stable, and she was referred to a combined rheumatology/obstetrics clinic. In the nineteenth week of pregnancy, she presented to the emergency department with multi organ involvement including acute confusion, multiple epileptic seizures, acute renal and cardiac insufficiency, and absence of foetal heartbeat. Haematology investigations showed thrombocytopaenia, reduced haptoglobins, and the presence of schistocytes on blood film in keeping with a microangiopathic haemolytic anaemia (MAHA). There was nephrotic range proteinuria (2300 mg/mmol) and creatinine had doubled from previous baseline to 109 micromol/L. Her condition became critical and she was transferred with life threatening thrombotic microangiopathy to the local tertiary centre for access to plasma exchange. She required intensive care admission with invasive ventilator support and a tracheostomy. Magnetic Resonance Imaging of her brain was consistent with posterior reversible encephalopathy syndrome (PRES). An echocardiogram showed moderate left ventricular systolic dysfunction with regional wall motion abnormalities. At nineteen gestational weeks, the presence of MAHA, thrombocytopaenia and acute renal injury was compatible with several possible overlapping diagnoses. This included sepsis with disseminated intravascular coagulation (DIC), anti-phospholipid syndrome, i6 11-12 October 2017 POSTER CASE REPORTS
IS ECULIZUMAB

